Abstract 5211
Background
Neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care in MIBC patients, although a limited survival benefit has been obtained compared with cystectomy alone. Pathologic response has been associated with survival, but, unfortunately, neither baseline clinical or pathological variables have demonstrated ability to predict which patients will benefit from NAC, pointing to the need of predictive biomarkers of NAC response to guide treatment decisions. The objective of this retrospective study was to identify a NAC response prediction signature integrating baseline clinical features, taxonomic subtypes, and RNA expression profile in MIBC patients.
Methods
Formalin-fixed paraffin-embedded pre-treatment tumor samples were collected by transurethral resection from 112 patients with MIBC stage T2-4N0/+M0 treated with NAC followed by cystectomy. Immunohistochemical-based taxonomic subtypes (BASQ-like, luminal-like, mixed) were established. Gene expression analysis was performed on the Nano String nCounter platform. A custom code set of a 41-gene panel involved in the DNA damage repair (DDR) and immune response pathways was used. Lasso and elastic net penalized logistic regression were performed to identify a predictive signature. Calculation of the area under the ROC curve (AUC) was used to assess the predictive ability of the signature.
Results
A nine-gene RNA expression signature (RAD51, CXCL9, PARP, 53BP1, HERC2, ERCC2, CHEK1, Ku80 and RNF 168 genes) was associated with pathologic response. The highest predictive ability was observed with the integrated clinical-taxonomical-RNA signature with an AUC of 0.66, in comparison to the clinical-taxonomical classification (AUC=0.58) or the clinical signature alone (AUC=0.52). Furthermore, the integrated signature was significantly associated with overall survival (p = 0.013).
Conclusions
We have identified a nine-gene RNA expression signature that can help to predict response in MIBC patients treated with NAC. Prospective studies are warranted to validate these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AECC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract